^
Association details:
| Biomarker: | BCR-ABL1 T315I |
|---|---|
| Cancer: | Acute Lymphocytic Leukemia |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Identification of Patient-Specific Anti-Apoptotic Molecules As Therapeutic Targets in Poor Prognosis Acute Lymphoblastic Leukemia (ALL)
Published date:
11/04/2021
Excerpt:
For Ph+ ALL/MPAL and CML, BIRC inhibitor and/or venetoclax combined with dexamethasone (DEX) and TKI achieved effective in vivo elimination of leukemic cells as predicted by in vitro experiments. Combination therapy showed almost complete elimination of Ph+ leukemic cells even in the presence of T315I mutation.
Secondary therapy:
Tyrosine Kinase Inhibitors;
DOI:
10.1182/blood-2021-147625
